Clinical Trial Update: Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a conditioning regimen using Campath, fludarabine, and melphalan for non-malignant diseases; currently recruiting in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Marrow Disorders
• Hematologic Disorders
• Hemoglobinopathy
• Immune System Disorders
• Metabolic Disorders
• Non-malignant Disorders

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• Fludarabine (Fludarabine)
• Melphalan (Melphalan)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders | Phase 1, Phase 2 | Status: RECRUITING